Abstract
White matter hyperintensities (WMH) and infarcts found on magnetic resonance imaging (MR infarcts) are common biomarkers of cerebrovascular disease. In this review, we summarize the methods, publications, and conclusions stemming from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) related to these measures. We combine analysis of WMH and MR infarct data from across the three main ADNI cohorts with a review of existing literature discussing new methodologies and scientific findings derived from these data. Although ADNI inclusion criteria were designed to minimize vascular risk factors and disease, data across all the ADNI cohorts found consistent trends of increasing WMH volumes associated with advancing age, female sex, and cognitive impairment. ADNI, initially proposed as a study to investigate biomarkers of AD pathology, has also helped elucidate the impact of asymptomatic cerebrovascular brain injury on cognition within a cohort relatively free of vascular disease. Future ADNI work will emphasize additional vascular biomarkers.
Highlights
White matter hyperintensities (WMHs) are common to advancing age and likely reflect brain vascular injury among older individuals.
WMH and to a lesser extent, magnetic resonance (MR) infarcts, affect risk for transition to cognitive impairment.
WMHs and MR infarcts are present, even among Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants highly selected to have Alzheimer’s disease (AD) as the primary pathology.
WMH burden in ADNI is greater among individuals with cognitive impairment and has been associated with AD neurodegenerative markers and cerebral amyloidosis.
The negative additive effects of cerebrovascular disease appear present, even in select populations, and future biomarker work needs to further explore this relationship.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Pauline Maillard,
Evan Fletcher,
Owen Carmichael,
Christopher Schwarz,
Stephan Seiler,
Charles DeCarli,
for the Alzheimer’s Disease Neuroimaging Initiative | November 13, 2024